{"groups":[{"description":"Patients receive cabozantinib S-malate PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or x-ray imaging during screening and on study.\\>\n\n\\> Cabozantinib S-malate: Given PO\\>\n\n\\> Computed Tomography: Undergo CT\\>\n\n\\> Magnetic Resonance Imaging: Undergo MRI\\>\n\n\\> Quality-of-Life Assessment: Ancillary studies\\>\n\n\\> X-Ray Imaging: Undergo x-ray","id":"FG000","title":"Arm Ia (Cabozantinib S-malate, Extra-pancreatic NET Cohort [epNET])"},{"description":"Patients receive placebo PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or x-ray imaging during screening and on study. Patients may crossover to receive cabozantinib S-malate at the time of disease progression.\\>\n\n\\> Computed Tomography: Undergo CT\\>\n\n\\> Magnetic Resonance Imaging: Undergo MRI\\>\n\n\\> Placebo Administration: Given PO\\>\n\n\\> Quality-of-Life Assessment: Ancillary studies\\>\n\n\\> X-Ray Imaging: Undergo x-ray","id":"FG001","title":"Arm IIa (Placebo, Extra-pancreatic NET Cohort [epNET])"},{"description":"Patients receive cabozantinib S-malate PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or x-ray imaging during screening and on study.\\>\n\n\\> Cabozantinib S-malate: Given PO\\>\n\n\\> Computed Tomography: Undergo CT\\>\n\n\\> Magnetic Resonance Imaging: Undergo MRI\\>\n\n\\> Quality-of-Life Assessment: Ancillary studies\\>\n\n\\> X-Ray Imaging: Undergo x-ray","id":"FG002","title":"Arm Ib (Cabozantinib S-malate, Pancreatic NET Cohort [pNET])"},{"description":"Patients receive placebo PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or x-ray imaging during screening and on study. Patients may crossover to receive cabozantinib S-malate at the time of disease progression.\\>\n\n\\> Computed Tomography: Undergo CT\\>\n\n\\> Magnetic Resonance Imaging: Undergo MRI\\>\n\n\\> Placebo Administration: Given PO\\>\n\n\\> Quality-of-Life Assessment: Ancillary studies\\>\n\n\\> X-Ray Imaging: Undergo x-ray","id":"FG003","title":"Arm IIb (Placebo, Pancreatic NET Cohort [pNET])"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"0"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"4"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"55"},{"groupId":"FG001","numSubjects":"41"},{"groupId":"FG002","numSubjects":"29"},{"groupId":"FG003","numSubjects":"24"}],"type":"Progressive disease"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}],"type":"Alternative treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"0"}],"type":"Other disease"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}],"type":"Withdrawal prior to initiation"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Non-compliance"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"134"},{"groupId":"FG001","numSubjects":"69"},{"groupId":"FG002","numSubjects":"64"},{"groupId":"FG003","numSubjects":"31"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"132"},{"groupId":"FG001","numSubjects":"67"},{"groupId":"FG002","numSubjects":"63"},{"groupId":"FG003","numSubjects":"31"}],"type":"Initiated Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"21"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"14"},{"groupId":"FG003","numSubjects":"2"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"113"},{"groupId":"FG001","numSubjects":"62"},{"groupId":"FG002","numSubjects":"50"},{"groupId":"FG003","numSubjects":"29"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}